Tenet Healthcare Corp Stock Price, News & Analysis

Tenet Healthcare (NYSE:THC) and its subsidiary USPI have been named foundational sponsors of the American Association of Orthopaedic Surgeons' (AAOS) inaugural Launchpad Program. The 20-month initiative is designed to support postgraduate year 5 (PGY5) orthopaedic surgery residents in their transition from residency to practice.

The program, launched as a pilot at the AAOS Annual Meeting in March 2025, will support three cohorts of PGY5 resident members over the next three and a half years. It focuses on fellowship navigation, preparation for American Board of Orthopaedic Surgery examinations, and building foundations for long-term success. AAOS plans to expand the program to include all PGY4 and PGY5 residents after the pilot phase.

Tenet Healthcare (NYSE:THC) reported strong Q2 2025 results with significant growth across key metrics. Net income reached $288 million ($3.14 per diluted share), while Adjusted EBITDA increased 18.6% to $1.121 billion with a 21.3% margin.

The company's Ambulatory Care segment showed robust performance with Adjusted EBITDA of $498 million, up 11.4% year-over-year. The Hospital segment delivered strong results with Adjusted EBITDA of $623 million, benefiting from favorable payer mix and higher acuity services.

Notably, the Board authorized a $1.5 billion increase to the share repurchase program. Tenet raised its FY 2025 outlook, now expecting Adjusted EBITDA between $4.40-$4.54 billion, a $395 million increase at the midpoint.

Tenet Healthcare (NYSE: THC) has announced it will release its Q2 2025 financial results on Tuesday, July 22nd, 2025, before market opening. Following the earnings release, the company will host a conference call at 9:00 a.m. Central Time (10:00 a.m. Eastern Time) to discuss the results. Investors and interested parties can access the live webcast and audio archive of the earnings call through Tenet's investor relations website at www.tenethealth.com/investors.

Tenet Healthcare Corporation (NYSE: THC) has announced its participation in the upcoming BofA Securities 2025 Health Care Conference. The company's presentation is scheduled for Tuesday, May 13, 2025, at 1:40 p.m. Eastern time. Investors and interested parties can access the live webcast through Tenet's investor relations website at www.tenethealth.com/investors. A replay of the presentation will remain available on the website for 30 days following the event.

Tenet Healthcare reported strong Q1 2025 financial results, with net income of $406 million ($4.27 per diluted share) and Adjusted EBITDA of $1.163 billion, marking a 13.6% increase from Q1 2024. The company's Ambulatory Care segment showed impressive growth with a 15.7% increase in Adjusted EBITDA to $456 million.

Key highlights include:

• Adjusted diluted EPS increased 35.4% to $4.36
• Strong cash flow of $815 million from operations
• Same-hospital admissions grew 4.4%
• Ambulatory segment revenue increased 20%

The company's 2025 outlook projects net operating revenues between $20.6-21.0 billion and Adjusted EBITDA of $3.975-4.175 billion. Tenet maintains a strong operational position with 520 ambulatory surgery centers and 25 surgical hospitals across 37 states, demonstrating continued expansion in high-quality specialty care delivery.

Tenet Healthcare (NYSE: THC) has announced it will release its first quarter 2025 financial results before market opening on Tuesday, April 29, 2025. The company will host a conference call at 9:00 a.m. CT (10:00 a.m. Eastern Time) on the same day to discuss the results. Investors can access both a live webcast and audio archive of the earnings call through the investor relations section of Tenet's website.

Tenet Healthcare (NYSE: THC) has announced its upcoming virtual participation in the Barclays 27th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, March 12, 2024, starting at 10:00 a.m. Eastern time.

Investors and interested parties can access the live webcast and audio archive through the investor relations section of Tenet's website at www.tenethealth.com/investors. The replay will remain available for a 30-day period following the presentation.

Tenet Healthcare (NYSE: THC) reported strong Q4 2024 results with net income of $318 million ($3.32 per diluted share) and Adjusted EBITDA of $1.048 billion. The company's Ambulatory Care segment showed impressive growth with Q4 Adjusted EBITDA increasing 14.2% to $530 million.

Key financial highlights include Q4 net operating revenues of $5.072 billion, down from $5.379 billion in Q4 2023 due to hospital divestitures, offset by strong same-facility revenue growth. For full-year 2024, the company achieved net income of $3.2 billion, including a $2.916 billion pre-tax gain from hospital divestitures.

The company's 2025 outlook projects net operating revenues between $20.6-21.0 billion and Adjusted EBITDA of $3.975-4.175 billion. Tenet also reported significant deleveraging, with its net debt to Adjusted EBITDA ratio improving to 2.54x from 3.89x year-over-year.

Tenet Healthcare (NYSE: THC) has announced it will release its fourth quarter 2024 financial results before market opening on Wednesday, February 12, 2025. The company will host a conference call at 9:00 a.m. CT (10:00 a.m. ET) on the same day to discuss the results. Investors can access both the live webcast and audio archive of the call through the investor relations section of Tenet's website.